Clinical Core

临床核心

基本信息

批准号：
10590696
负责人：
ROBERT A SWEET
金额：
$ 108.61万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-15 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10590696
关键词：
Acceleration Achievement Age Agreement Alzheimer disease prevention Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Amyloid Autopsy Biological Biological Markers Blood specimen Brain Brain imaging Classification Clinical Clinical Data Clinical Services Clinical Trials Collaborations Collection Complex Consent DNA Data Dementia Development Diagnosis Education Enrollment Evaluation Frontotemporal Lobar Degenerations Funding Genetic Goals Impaired cognition Impairment Individual International Intervention Investigation Knowledge Lead Leadership Measures Minority Recruitment National Institute on Alcohol Abuse and Alcoholism Natural History Nerve Degeneration Normalcy Parkinsonian Disorders Participant Patients Plasma Population Prevention Procedures Productivity Psychoses Recording of previous events Research Research Personnel Research Project Grants Research Support Resources Role Sampling Testing Tissues Training Universities Visit amyloid imaging biomarker evaluation cognitive testing cohort data management flexibility follow-up genome wide association study informant meetings mild cognitive impairment neurogenetics neuroimaging neuropathology neuropsychiatric symptom neuropsychiatry next generation outreach participant enrollment performance tests pre-clinical psychiatric comorbidity recruit referral services repository research study tau Proteins trial readiness

项目摘要

Core B: Clinical Core Summary/Abstract: Progress in the diagnosis, treatment, and prevention of Alzheimer’s Disease (AD) depends critically on the availability of large “trial-ready” cohorts of participants spanning the transition from normal through preclinical AD stages, mild cognitive impairment (MCI), to early AD. The PITT-ADRC Clinical Core has effectively accomplished this, evaluating a cohort of more than 4700 participants since its inception and providing participants, biologic samples, and data for a wide array of studies that depend critically on differing clinical populations: participants at risk for AD (e.g. prevention, biomarker studies); participants with clinical AD (e.g. GWAS of AD, GWAS of psychosis); participants with autopsy-confirmed AD (e.g. postmortem-tissue studies); and participants with other dementias (e.g. DLB consortium). The Clinical Core has developed approaches to maximize flexibility in meeting the needs of these diverse, and evolving, set of supported investigations. In addition to its role as a critical resource for many funded studies in the PITT-ADRC, the Clinical Core will provide participants that will serve as a focus for biomarker evaluation by the Neuroimaging Core and the Biomarker and Neurogenetics Core. During the current period we have also maintained our strong history of neuropsychiatric characterization of all participants and further enhanced our rate of autopsy consent, supporting the Neuropathology Core and multiple affiliated R01s. We have continued our strong record of providing genetic samples and data on large numbers of participants annually for use in local R01s and in national and international consortia. Finally, we have added new investigators with specialized expertise in Parkinsonian syndromes and FTLD and have developed new procedures to increase the rate of completed follow-up visits for our participants. These accomplishments have prepared the Clinical Core to maintain its productivity in the following set of proposed Specific Aims: 1) To perform evaluations at study entry and at annual follow-up of Normal Control, pre-MCI, MCI, AD, and related dementia participants participating in the PITT-ADRC; 2) To assure maximum participation in clinical, intervention, brain imaging, biomarker, and autopsy studies by providing appropriate research study referrals and clinical services during longitudinal follow-up; 3) To provide clinical data, research participants, DNA samples, and technical and scientific leadership to support new and ongoing research projects at the PITT-ADRC, within and outside the University of Pittsburgh, and to support national consortium studies; 4) In collaboration with the Outreach, Recruitment, and Engagement Core, to facilitate recruitment and retention of diverse participants; 5) To support the Research and Education Component in training the next generation of dementia researchers by providing research participants, samples, and data.

核心 B：临床核心摘要/摘要：阿尔茨海默病 (AD) 的诊断、治疗和预防方面的进展关键取决于拥有大量“试验就绪”参与者，涵盖从正常到临床前的过渡 AD 阶段、轻度认知障碍 (MCI) 到早期 AD PITT-ADRC 临床核心有效。这项工作自成立以来对超过 4700 名参与者进行了评估，并提供了广泛研究的参与者、生物样本和数据，这些研究主要取决于不同的临床人群：有 AD 风险的参与者（例如预防、生物标志物研究）；患有临床 AD 的参与者（例如 AD 的 GWAS、精神病的 GWAS）；尸检确诊的 AD 参与者（例如死后组织研究）；以及患有其他痴呆症的参与者（例如 DLB 联盟）已开发出治疗方法。最大限度地提高灵活性，满足这些多样化且不断发展的受支持调查的需求。除了作为 PITT-ADRC 中许多资助研究的关键资源外，临床核心还将提供参与者将成为神经影像核心和生物标志物评估生物标志物的重点在当前时期，我们还保持了我们强大的历史。所有参与者的神经精神特征，并进一步提高了我们的尸检同意率，支持我们继续保持提供神经病理学核心和多个附属 R01 的良好记录。每年大量参与者的基因样本和数据用于当地 R01 以及国家和地区最后，我们增加了具有帕金森病专业知识的新研究人员。综合症和 FTLD，并开发了新程序来提高完成随访的比率这些成就为临床核心保持其生产力做好了准备。以下一组拟议的具体目标： 1) 在研究开始时和年度随访时进行评估参加 PITT-ADRC 的正常对照、MCI 前期、MCI、AD 和相关痴呆参与者 2) 确保最大限度地参与临床、干预、脑成像、生物标志物和尸检研究 3) 在纵向随访期间提供适当的研究转介和临床服务；临床数据、研究参与者、DNA 样本以及技术和科学领导力，以支持新的和匹兹堡大学内外的 PITT-ADRC 正在进行的研究项目，并支持国家联盟研究；4) 与外展、招聘和参与核心合作，促进招募和保留不同的参与者； 5) 支持研究和教育；通过提供研究参与者、样本、和数据。